Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Menopause Market

ID: MRFR/HC/66570-CR
128 Pages
Snehal Singh, Rahul Gotadki
Last Updated: May 07, 2026

Menopause Market Research Report: Information by Treatment Type (Hormone Therapy, Non-Hormonal Treatment, and dietary supplements), By Menopause Stage (menopause, perimenopause, and post-menopause), By Application (Hot Flashes and Night Sweats (Vasomotor Symptoms), Vaginal Dryness and Atrophy, Sleep Disturbances, Mood Swings and Depression, Bone Health, and Urinary Symptoms), By Distribution Channel (hospital pharmacy, retail pharmacy, and online channels.)By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) -Global Forecast to 2035.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Menopause Market Infographic
Purchase Options

Menopause Market Summary

As per MRFR analysis, Menopause Market Menopause Stage was valued at USD 16,994.32 million in 2024. The Menopause Industry is projected to grow from USD 17,628.21 million in 2025 to USD 30,415.70 million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.7% during the forecast period (2025 - 2035).

Key Market Trends & Highlights

The Menopause Market is the deep integration of artificial intelligence (AI) and machine learning (ML) for advanced signal processing.

  • Innovation in menopause management is increasingly focused on finding safer, long-term alternatives to traditional Hormone Replacement Therapy (HRT).
  • Technology is playing an increasingly vital role in how women access care and manage their health during menopause.
  • Consumer segment of the menopause market, particularly dietary supplements and lifestyle-based solutions, continues to dominate in terms of market share.
  • Women are more engaged in self-care, seeking solutions that integrate into their daily routines rather than relying solely on acute medical intervention.

Market Size & Forecast

2024 Market Size 16,994.32 (USD Million)
2035 Market Size 30,415.70 (USD Million)
CAGR (2025 - 2035) 5.7%

Major Players

Sparton Corporation, Thales Group, ASELSAN A.Ş., Bharat Dynamics Limited (BDL), L3Harris Technologies, Inc, Radixon Group, Ultra Group.

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Menopause Market Trends

Development of Non-Hormonal Therapies

The development of non-hormonal Neurokinin 3 (NK3) receptor antagonists represents a transformative opportunity for the Menopause Market, particularly for women who are unsuitable for or averse to traditional hormone therapy (HT). These therapies target the "KNDy" neurons in the hypothalamus, which become overactive due to estrogen depletion and disrupt the body's thermoregulatory center. By blocking neurokinin B (NKB) signaling at the NK3 receptor, these drugs restore thermoregulatory balance without the systemic risks associated with estrogen, such as blood clots or hormone-sensitive cancers.

Focus on Menopause at the Workplace

The increasing recognition of menopause as a significant workplace health issue presents a substantial opportunity for market growth in products, services, and workplace policies tailored to menopausal women. As women constitute nearly half of the global workforce, addressing menopausal health can enhance employee well-being, productivity, and retention. According to the World Health Organization, approximately 50% of women globally experience menopause between ages 45 and 55, highlighting the widespread relevance of this phase.

In recent years, there has been a growing movement toward workplace inclusivity, with companies like Deloitte and Johnson & Johnson implementing menopause-friendly policies that include flexible work arrangements, awareness programs, and health support services. For example, a 2021 survey by the UK’s Menopause Support found that 51% of women in the workplace experienced menopause-related symptoms affecting their performance, underscoring the need for targeted support

Menopause Market Drivers

Shift Towards Non-Hormonal and Dietary Supplements

The increasing shift toward non-hormonal therapies and dietary supplements as a primary approach to managing menopause symptoms is a significant growth driver for the Menopause Market. Women seeking alternatives to hormone replacement therapy (HRT), which has been associated with certain health risks such as an increased likelihood of breast cancer and cardiovascular conditions, are increasingly turning to natural and dietary options.

Expanding acceptance of hormone therapy (HT) post-WHI re-evaluation

The expanded acceptance of hormone therapy (HT) following the re-evaluation of findings from the Women's Health Initiative (WHI) has significantly influenced the Menopause Market. The WHI, initially launched in 1991, aimed to evaluate the health benefits and risks of HT in postmenopausal women. Moreover, advancements in formulations such as bioidentical hormones and transdermal delivery systems offer safer and more personalized treatment options, further driving acceptance. Regulatory bodies, including the U.S. Food and Drug Administration (FDA), have also updated guidelines to reflect current evidence, supporting more informed decision-making. Overall, the re-evaluation of WHI data has led to a more balanced perspective, fostering greater confidence among both patients and clinicians in the use of hormone therapy, and thereby supporting the continued growth of the Menopause Market.

Market Segment Insights

By Treatment Type: Hormone Therapy (largest market) vs Non-Hormonal Treatment (fastest growing)

Based on treatment, the Menopause Market has been segmented into Hormone Therapy, Non-Hormonal Treatment, and dietary supplements. The Hormone Therapy segment held the largest market in 2025, and the Non-Hormonal Therapy segment is the fastest growing segment during the forecast period.

By Menopause Stage: perimenopause (largest market) vs post menopause (fastest-growing)

Based on menopause stage, the Menopause Market has been segmented into premature menopause, perimenopause, and postmenopause. The Perimenopause segment held the largest market in 2025, and the Perimenopause segment is the fastest growing segment during the forecast period.

By Application: Hot Flashes and Night Sweats (largest market) vs Bone Health (fastest-Growing)

Based on application, the Menopause Market has been segmented into Hot Flashes and Night Sweats (Vasomotor Symptoms), Vaginal Dryness and Atrophy, Sleep Disturbances, Mood Swings and Depression, Bone Health, and Urinary Symptoms. The Hot Flashes and Night Sweats (Vasomotor Symptoms) segment held the largest market in 2025, and the Sleep Disturbances segment is the fastest growing segment during the forecast period.

By Distribution channel: hospital pharmacy (largest market) vs retail pharmacy (fastest-Growing)

Based on distribution channel, the Menopause Market has been segmented into hospital pharmacy, retail pharmacy, and online channels. The Hospital Pharmacies segment held the largest market in 2025, and the Online Channels segment is the fastest growing segment during the forecast period.

Get more detailed insights about Menopause Market

Regional Insights

North America: Expanding high consumer engagement

North America remains the global leader in the menopause market, supported by strong healthcare infrastructure, widespread education, and high consumer engagement. The U.S. accounts for the vast majority of this regional share. Market dynamics are characterized by a robust demand for both traditional hormone replacement therapies (HRT) and an expanding segment of non-hormonal, prescription-based alternatives. Telemedicine has emerged as a critical driver, facilitating easier access to specialized care and reducing the stigma often associated with menopausal health.

Europe: Strong Production high rates of clinical diagnosis

Europe follows as a significant market, bolstered by comprehensive public healthcare systems that often subsidize menopause-related treatments, such as HRT in the UK and various EU nations. This structured access encourages high rates of clinical diagnosis and sustained treatment adherence. Dietary supplements represent the largest revenue segment, as many women lean toward holistic and over-the-counter solutions alongside conventional medical care. The region is seeing a steady, moderate growth trajectory as it integrates advanced digital health solutions with existing clinical networks.

Asia Pacific: Growing escalating health consciousness

The APAC region is positioned for the most significant growth, driven by a massive, aging female population and a rapid rise in health consciousness. Market expansion here is unique due to the intersection of Western medical approaches with traditional practices like acupuncture and herbal medicine. Dietary supplements focused on brain, heart, and bone health are seeing high consumer uptake, supported by the proliferation of e-commerce platforms. Efforts to increase societal awareness and reduce cultural stigma are further accelerating the adoption of menopause-specific wellness products.

South America: Protection of health access

South America represents an emerging frontier in the menopause market. Growth is driven by an aging demographic that is increasingly vocal about their specific healthcare needs. Similar to other emerging regions, there is a strong focus on affordable, accessible over-the-counter options and dietary supplements. As awareness grows through local health advocacy and the expansion of digital health access, the region is poised for continued, incremental growth, bridging the gap between historical medical neglect and modern, proactive management.

Middle East & Africa: Emerging health access

The Middle East & Africa (MEA) region is emerging as a steady but smaller sonobuoy market, driven by maritime security imperatives and strategic waterways protection requirements. Countries such as Saudi Arabia, the United Arab Emirates, and Egypt have been expanding sonar and sonobuoy systems to monitor areas like the Persian Gulf and Red Sea, where piracy, border security, and critical shipping routes demand enhanced underwater surveillance. South Africa also contributes through coastal monitoring and research activities. While overall market share is lower compared to North America and Europe, MEA growth reflects increased defense spending, naval modernization, and a rising focus on maritime situational awareness. As regional actors pursue infrastructure protection and joint security initiatives, sonobuoys serve as critical acoustic sensors for ASW and surveillance missions across strategic chokepoints.

Menopause Market Regional Insights

Key Players and Competitive Insights

Many global, regional, and local vendors characterize the Menopause Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in Treatment, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.
The major players in the market Include Astellas Pharma Inc., Amgen Inc., Novartis AG, Pfizer Inc., Bayer AG, Teva Pharmaceutical Industries Ltd, Sandoz Group Ag, AbbVie Inc., strategic market developments and decisions to improve operational effectiveness.

Key Companies in the Menopause Market include

Industry Developments

August 2025: Theramex received regulatory approval across Europe and the UK for Bijuva / Bijuve, a combined hormone replacement therapy containing estradiol (1 mg) and progesterone (100 mg). It is the first and only body-identical HRT that combines both hormones in a single daily oral capsule for post-menopausal women with an intact uterus. The formulation uses hormones identical to those naturally produced in the body, offering a safer alternative to synthetic therapies, with real-world evidence indicating lower risks of venous thromboembolism, breast cancer, cardiovascular disease, and stroke. The approval also marks a significant advancement in treatment options for moderate to severe vasomotor symptoms associated with menopause.

April 2025: Real-world study of ~478,651 postmenopausal women showed Prolia reduced fracture risk vs. alendronate, including 36% lower hip fracture risk and 43% lower non-vertebral fracture risk. Risk reduction improved with longer treatment duration, reaching 31% reduction in major osteoporotic fractures by year.

March 2026: Health Canada as the first non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause. The launch is supported by the BRIGHT SKY Phase 3 program (SKYLIGHT 1, 2, and 4 trials) involving over 2,850 patients across the US, Canada, and Europe, demonstrating efficacy in reducing hot flashes and night sweats and establishing long-term safety. The therapy works via neurokinin B receptor antagonism in the hypothalamus. It has also received approvals in the US, UK, Australia, and Europe, with ongoing Phase 3 evaluation (HIGHLIGHT 1) in breast cancer patients. 

Future Outlook

Menopause Market Future Outlook

The Menopause Market is projected to grow at a 5.7% CAGR from 2025 to 2035, driven by increasing demand for high-performance computing and enhanced security features.

New opportunities lie in:

  • Development of Non-Hormonal Therapies.
    Focus on Menopause at the Workplace.

Market Segmentation

Menopause Market by Application Outlook

  • Hot Flashes and Night Sweats
  • Vaginal Dryness and Atrophy
  • Sleep Disturbances
  • Mood Swings and Depression
  • Bone Health
  • Urinary Symptoms

Menopause Market by Treatment Type Outlook

  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements

Menopause Market by Menopause Stage Outlook

  • Premature Menopause
  • Perimenopause
  • Postmenopause

Menopause Market by Distribution Channel Outlook

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels

Report Scope

Market Menopause Stage 2024

16,994.32 (USD Million)

Market Menopause Stage 2025

17,628.21 (USD Million)

Market Menopause Stage 2035

30,415.70 (USD Million)

Compound Annual Growth Rate (CAGR)

5.7% (2025 - 2035)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Base Year

2024

Market Forecast Period

2025 - 2035

Historical Data

2019 - 2023

Market Forecast Units

USD Million

Key Companies Profiled

Astellas Pharma Inc., Amgen Inc., Novartis AG, Pfizer Inc., Bayer AG, Teva Pharmaceutical Industries Ltd, Sandoz Group Ag, AbbVie Inc.

Segments Covered

By Treatment Type

By Menopause Stage

By Application

By Distribution Channel

Key Market Opportunities

Development of Non-Hormonal Therapies

Focus on Menopause at the Workplace.

Key Market Dynamics

Expanding acceptance of hormone therapy (HT) post-WHI re-evaluation

Shift Towards Non-Hormonal and Dietary Supplements

Growth in Online Channels & Telehealth

Innovation in Delivery Systems.

Region Covered

North America, Europe, Asia Pacific, South America, Middle East & Africa.

FAQs

How much is the Menopause Market?

USD 30,415.70 Million (2035) is the Menopause Market

What is the growth rate of the Menopause Market?

5.7% is the growth rate of the Menopause Market

Which region held the largest market share in the Menopause Market?

North America held the largest market share in the Menopause Market.

Who are the key players in the Menopause Market?

Astellas Pharma Inc., Amgen Inc., Novartis AG, Pfizer Inc., Bayer AG, Teva Pharmaceutical Industries Ltd, Sandoz Group Ag, AbbVie Inc are the key players in the Menopause Market.

Which distribution Channel had the largest market share in the Menopause Market?

hospital pharmacy had the largest market share in the Menopause Market.
Author
Author
Author Profile
Snehal Singh LinkedIn
Manager - Research
High acumen in analyzing complex macro & micro markets with more than 6 years of work experience in the field of market research. By implementing her analytical skills in forecasting and estimation into market research reports, she has expertise in Packaging, Construction, and Equipment domains. She handles a team size of 20-25 resources and ensures smooth running of the projects, associated marketing activities, and client servicing.
Co-Author
Co-Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Leave a Comment
Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions